Page 169 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

23. Garden GM, Ayres JG. Psychiatric and social aspects of brittle asthma. Thorax 1993;48(5):501-5.
24. Grootendorst DC, Dahlen SE, Van Den Bos JW, et al. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose
inhaled steroids. Clin Exp Allergy 2001; 31:400-8.
25. Karagiannidis C, Hense G, Rueckert B, et al. High-altitude climate therapy reduces local airway
inflammation and modulates lymphocyte activation. Scand J Immunol 2006; 63:304-10.
26. Rijssenbeek-Nouwens LH, Bel EH. High-altitude treatment: a therapeutic option for patients with
severe, refractory asthma? Clin Exp Allergy 2011;41:775-82.
27. Rijssenbeek-Nouwens LH, Fieten KB, Bron AO, Hashimoto S, Bel EH, Weersink EJ. High-altitude
treatment in atopic and nonatopic patients with severe asthma. Eur Respir J. 2012;40(6):1374-80.
28. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding
pulmonary diseases. Chest 2010;137:1410-6.
29. Heaney LG, McGarvey LP. Personalised Medicine for Asthma and Chronic Obstructive Pulmonary
Disease. Respiration. 2017;93(3):153-161.
30. Wilson LS, Maeder AJ. Recent Directions in Telemedicine: Review of Trends in Research and Practice.
Healthc Inform Res. 2015 21(4):213-22.
31. Cooper CB. Respiratory applications of telemedicine. Thorax 2009; 64:189-191.
32. Reed ME1, Parikh R2, Huang J3, Ballard DW4, Barr I5, Wargon C6. Real-Time Patient-Provider Video
Telemedicine Integrated with Clinical Care. N Engl J Med. 2018 11;379(15):1478-1479.
33. Weinstein RS, Krupinski EA, Doarn CR. Clinical Examination Component of Telemedicine, Telehealth,
mHealth, and Connected Health Medical Practices. Med Clin North Am. 2018;102(3):533-544.
34. Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H, Störk S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F, Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group,
unmasked trial. Lancet. 2018;392(10152):1047-1057.
35. O’Connor DM, Jew OS, Perman MJ, Castelo-Soccio LA, Winston FK, McMahon PJ.Diagnostic
Accuracy of Pediatric Teledermatology Using Parent-Submitted Photographs: A Randomized
Clinical Trial. JAMA Dermatol. 2017;153(12):1243-1248.
36. de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M,
van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959-968.
37. Bilocca D, Hargadon B, Pavord ID, Green RH, Brightling CE, Bradding P, Wardlaw AJ, Martin N, Murphy AC, Siddiqui S. The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma. Chron Respir Dis. 2018;15(1):85-87.
38. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002993.
39. Bernstein IL, Bernstein DI, Dubb JW, et al. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol 1996;98:317-24.
40. Borish L. The immunology of asthma: asthma phenotypes and their implications for personalized treatment. Ann Allergy Asthma Immunol 2016;117:108–114
41. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2018 Dec 10. doi: 10.1164/rccm.201810-1944CI. [Epub ahead of print]
42. Chung KF. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med. 2018;24(1):4-10.
43. Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016;9:CD011440.
44. Peters MC, Kerr S, Dunican EM, Woodruff PG, Fajt ML, Levy BD, Israel E, Phillips BR, Mauger DT, Comhair SA, Erzurum SC, Johansson MW, Jarjour NN, Coverstone AM, Castro M, Hastie AT, Bleecker ER, Wenzel SE, Fahy JV; National Heart, Lung and Blood Institute Severe Asthma Research Program 3. Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 2018 Mar 7. pii: S0091-6749(18)30390-7. doi: 10.1016/j.jaci.2017.12.1009. [Epub ahead of print]
45. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189–1197.
46. https://ginasthma.org/wp-content/uploads/2018/11/GINA-SA-FINAL-wms.pdf (last accessed December 2018)
Summary and general discussion
167
10